|
SPOPL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.68259999950338E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.31779999999571E-05 |
| Normal-vs-Stage2 |
4.42620000000726E-05 |
| Normal-vs-Stage3 |
3.01270000002685E-06 |
| Normal-vs-Stage4 |
1.51387999999253E-05 |
| Stage1-vs-Stage2 |
2.453200E-01 |
| Stage1-vs-Stage3 |
3.906800E-01 |
| Stage1-vs-Stage4 |
2.475200E-01 |
| Stage2-vs-Stage3 |
6.087000E-01 |
| Stage2-vs-Stage4 |
9.594000E-01 |
| Stage3-vs-Stage4 |
6.234200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.32460000038471E-07 |
| Normal-vs-AfricanAmerican |
1.102190E-01 |
| Normal-vs-Asian |
3.236000E-04 |
| Caucasian-vs-AfricanAmerican |
1.154180E-01 |
| Caucasian-vs-Asian |
9.455200E-01 |
| AfricanAmerican-vs-Asian |
1.967620E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.90329999725381E-08 |
| Normal-vs-Female |
1.80160999999623E-05 |
| Male-vs-Female |
1.267350E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.753500E-04 |
| Normal-vs-Age(41-60Yrs) |
2.7977999994544E-07 |
| Normal-vs-Age(61-80Yrs) |
3.8060000000506E-06 |
| Normal-vs-Age(81-100Yrs) |
1.150080E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.026400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.540570E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.237600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.052000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.333800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.804000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.186600E-01 |
| Classical-VS-Follicular |
5.369300E-04 |
| Classical-VS-Other |
2.206000E-01 |
| Classical-VS-Normal |
2.045500E-04 |
| Tall-VS-Follicular |
2.318400E-01 |
| Tall-VS-Other |
4.235800E-01 |
| Tall-VS-Normal |
5.377700E-04 |
| Follicular-VS-Other |
9.490200E-01 |
| Follicular-VS-Normal |
4.4771999996307E-08 |
| Other-VS-Normal |
1.036350E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.54430000010031E-07 |
| Normal-vs-N1 |
1.90985999999338E-05 |
| N0-vs-N1 |
7.781600E-01 |
|
|
